BRCA Positive
Understanding a BRCA positive diagnosis? This resource provides essential information for healthcare professionals on BRCA1/2 positive and BRCA mutation carrier status, covering clinical documentation best practices and medical coding guidelines related to BRCA mutations. Learn about managing patient care for individuals with a BRCA positive result.
Inherited genetic mutations increasing risks for breast, ovarian, and other cancers.
Often no visible signs until cancer develops. Family history of these cancers is a key indicator.
Genetic counseling, oncology clinics, primary care for screening and risk management.
ICD-10 Code Families
Complete code families applicable to Z15.01
When to use each related code
| Description | When to use |
|---|---|
| Inherited mutation increasing breast/ovarian cancer risk. | Confirmed BRCA1 or BRCA2 pathogenic variant detected by genetic testing. |
| Elevated breast cancer risk, no known BRCA mutation. | Increased risk based on family history, models, or other factors but BRCA negative. |
| Variant of uncertain significance found in BRCA gene. | BRCA VUS detected; clinical significance unknown, requires further investigation. |
Best-practice checklist
- ✓BRCA1/2 genetic test result positive
- ✓Document specific BRCA mutation(s) detected
- ✓Family history of breast/ovarian cancer
- ✓Date of genetic testing and lab name
- ✓Impact on treatment plan if applicable
Common pitfalls to avoid
Missing documentation specifying which BRCA gene (1 or 2) is affected, impacting accurate coding and reimbursement.
Lack of clear documentation confirming positive genetic test result for BRCA, leading to potential coding errors and compliance issues.
Inconsistent documentation between personal/family history of cancer and BRCA status, creating coding ambiguity and audit vulnerability.
Best-practice tips
- 01Genetic counseling for risk assessment, family planning (ICD-10 Z13.8, Z31.5)
- 02Prophylactic mastectomy or oophorectomy discussions, risk reduction (ICD-10 Z40.0)
- 03Increased surveillance: mammograms, MRIs, transvaginal ultrasounds (CPT 77055, 77056)
- 04Chemoprevention options, discussions, documented informed consent (ICD-10 Z51.81, Z79.89)
- 05BRCA1/2 variant classification documented, clinical significance clarified (ICD-10 Z13.8)
Step-by-step checklist
- 1
Confirm genetic test report documents BRCA1 or BRCA2 mutation.
- 2
Verify patient understands implications of positive result.
- 3
Document family history of breast, ovarian, or related cancers.
- 4
Review NCCN guidelines for BRCA mutation carriers (screening, risk reduction).
Ready-to-paste narrative
Patient presents for genetic counseling and risk assessment due to family history of breast cancer and ovarian cancer. Genetic testing was performed revealing a positive BRCA mutation, confirming the diagnosis of BRCA Positive. The patient is a confirmed BRCA mutation carrier, also referred to as BRCA1/2 positive. This significantly increases her lifetime risk of developing breast cancer, ovarian cancer, and potentially other cancers such as fallopian tube cancer, peritoneal cancer, and male breast cancer. Pre-test genetic counseling included discussion of potential results, implications for medical management, and options for risk reduction strategies. Post-test counseling addressed the specific BRCA mutation identified, personalized risk assessment, and recommendations for enhanced surveillance including breast MRI, mammogram, and pelvic ultrasounds. Prophylactic mastectomy and prophylactic oophorectomy were discussed as risk-reducing surgical options. Chemoprevention strategies were also reviewed. The patient will be referred to a high-risk breast clinic for ongoing monitoring and management. ICD-10 code Z15.01 (genetic susceptibility to malignant neoplasm of breast) and Z15.02 (genetic susceptibility to malignant neoplasm of ovary) are applicable. This documentation supports medical necessity for increased surveillance and consideration of risk-reducing interventions. Referral to support groups and psychological counseling was offered to address potential emotional impact. The patient demonstrates understanding of the diagnosis, implications, and management plan. Further genetic counseling sessions are scheduled to address family member testing and cascade testing recommendations.
Common questions and answers
What are the most current NCCN guidelines for breast cancer screening and risk reduction strategies in patients with a BRCA1/2 positive result?+
The National Comprehensive Cancer Network (NCCN) guidelines recommend enhanced screening and risk-reducing options for BRCA1/2 mutation carriers. These include more frequent breast MRI and mammogram screenings starting at a younger age, often beginning at age 25 or based on individual risk assessment. Risk-reducing medications, such as tamoxifen and raloxifene, are also options to consider discussing with patients. Prophylactic mastectomy and salpingo-oophorectomy are surgical options that significantly reduce the risk of breast and ovarian cancer. Explore how the latest NCCN guidelines incorporate personalized risk stratification based on factors such as family history and specific mutation type for tailored management of BRCA1/2 positive individuals.
How do I effectively communicate BRCA1/2 positive results and management options with patients, including discussing potential surgical interventions like prophylactic mastectomy?+
Communicating BRCA1/2 positive results requires a sensitive and comprehensive approach. Clearly explain the increased cancer risk associated with the specific mutation, and detail the range of screening and risk-reducing options, including enhanced surveillance with breast MRI and mammography, chemoprevention, and the possibility of prophylactic mastectomy and/or salpingo-oophorectomy. Provide tailored information based on the patient's age, family history, and personal preferences. Genetic counseling referral is essential for further risk assessment, family cascade testing, and emotional support. Consider implementing decision aids and resources to facilitate shared decision-making regarding complex choices like prophylactic surgery. Engage in open discussions about potential physical and psychological impacts of each option to empower patients to make informed decisions that align with their values and goals.
Beyond breast and ovarian cancer, what other cancers are associated with BRCA1/2 mutations, and what screening or surveillance protocols should clinicians consider for BRCA positive patients?+
While BRCA1/2 mutations are most strongly associated with increased risks of breast and ovarian cancers, they also confer elevated risks for other malignancies including pancreatic cancer, melanoma, prostate cancer, and fallopian tube cancer. For BRCA1/2 positive individuals, clinicians should incorporate a broader risk assessment. Discuss potential screening strategies for these additional cancers, and tailor recommendations based on individual risk factors and family history. Learn more about emerging research on risk stratification models and targeted screening approaches for BRCA1/2-associated cancers beyond breast and ovary to provide comprehensive care for these patients.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.